Drug Trial Radar · NCT06589713
Effect of Renal Impairment on Enpatoran Pharmacokinetics
Last checked: Nov 19, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
34
Actual
Start
Sep 24, 2024
Primary completion
Apr 13, 2026
Study completion Apr 13, 2026
Sponsor
- Lead sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyIndustry
- Sponsor type
- Industry
- Collaborators
- Merck KGaA, Darmstadt, Germany
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the effect of renal impairment on the pharmacokinetics of enpatoran.
Conditions
- Renal Impairment
Interventions
EnpatoranDrug
Participants will receive a single oral dose of enpataron tablets once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetic (PK) Plasma Concentrations of EnpatoranTime frame: Predose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, and 48 hours postdose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CRS Clinical Research Services Kiel GmbH
Kiel, Schleswig-Holstein, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.